Active Ingredient History

  • Now
Velusetrag (INN, USAN; previously known as TD-5108) is an experimental drug candidate for the treatment of gastric neuromuscular disorders including gastroparesis, and lower gastrointestinal motility disorders including chronic idiopathic constipation and irritable bowel syndrome. It is a potent, selective, high efficacy 5-HT4 receptor serotonin agonist being developed by Theravance Biopharma and Alfa Wassermann. Velusetrag demonstrates less selectivity for other serotonin receptors, such as 5-HT2 and 5-HT3, to earlier generation 5-HT agonists like cisapride and tegaserod.   Wikipedia

  • SMILES: CC(C)N1C(=O)C(=Cc2ccccc12)C(=O)N[C@H]3C[C@H]4CC[C@@H](C3)N4C[C@@H](O)CN(C)S(=O)(=O)C
  • Mol. Mass: 504.65
  • ALogP: 1.56
  • ChEMBL Molecule:
More Chemistry
1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid ((1s,3r,5r)-8-((r)-2-hydroxy-3-(methanesulfonyl-methyl-amino)propyl)-8-aza-bicyclo(3.2.1)oct-3-yl)amide | td5108 | td-5108 | velusetrag


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue